The grades of six Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Elan (NYSE:ELN) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Elan engages in research, development, and commercial activities primarily in the areas of Alzheimers disease, Parkinsons disease, and multiple sclerosis (MS). For more information, get Portfolio Grader’s complete analysis of ELN stock.
This week, Eli Lilly (NYSE:LLY) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Eli Lilly discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. For more information, get Portfolio Grader’s complete analysis of LLY stock.
Merck‘s (NYSE:MRK) ratings are looking better this week, moving up to an A from last week’s B. Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. For more information, get Portfolio Grader’s complete analysis of MRK stock.
Pfizer (NYSE:PFE) is seeing ratings go up from a B last week to an A this week. Pfizer is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. For more information, get Portfolio Grader’s complete analysis of PFE stock.
Lannett Co.‘s (AMEX:LCI) gets a higher grade this week, advancing from a C last week to a B. Lannett manufactures and distributes pharmaceutical products under its own trade name and under generic names. Shares of LCI have increased 15.2% over the past month, more than the 2% rise the S&P 500 experienced over the same time. For more information, get Portfolio Grader’s complete analysis of LCI stock.
Acura Pharmaceuticals (NASDAQ:ACUR) shows solid improvement this week. The company’s rating rises from a C to a B. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.